

Ref: P01/2014/JJB

21 Jan 2014

### Direct Healthcare Professional Communication

#### **Combined hormonal contraceptives: be aware of the difference in risk of thromboembolism between products, the importance of individual risk factors and remain vigilant for signs and symptoms**

Dear HEALTHCARE PROFESSIONAL,

This letter is to inform you of the results of a Europe-wide review and the latest evidence on the risk of thromboembolism in association with certain combined hormonal contraceptives<sup>1</sup> (CHCs). The letter is intended for all prescribers of contraception and any healthcare professional that may be presented with a possible thromboembolism due to CHCs and has been agreed with the European Medicines Agency (EMA), the marketing authorisation holders and the Malta Medicines Authority.

#### **Summary**

- **This review confirmed previous understanding that the level of VTE risk with all low dose CHCs (ethinylestradiol <50µg) is small.**
- **There is good evidence for differences between CHCs in their risk of venous thromboembolism (VTE), depending on the type of progestogen they contain. Currently available data indicate that CHCs containing the progestogens levonorgestrel, norethisterone or norgestimate have the lowest risk of VTE among combined hormonal contraceptives (see table 1 below).**
- **When prescribing CHCs, careful consideration should be given to the individual woman's current risk factors, particularly those for VTE, and the difference in risk of VTE between products.**
- **A woman who has been using her combined contraceptive without any problems does not need to stop using it.**
- **There is no evidence for differences between low dose CHCs (ethinylestradiol <50µg) in their risk of arterial thromboembolism (ATE).**
- **The benefits associated with using a CHC far outweigh the risk of serious side effects in most women. The focus is now on emphasising the importance of an individual woman's risk factors and the need to regularly reassess them, and raising awareness of the signs and symptoms of VTE and ATE which should be described to women when a CHC is prescribed.**

---

<sup>1</sup> Combined hormonal contraceptives containing ethinylestradiol or estradiol associated with chlormadinone, desogestrel, dienogest, drospirenone, etonogestrel, gestodene, nomegestrol, norelgestromin or norgestimate.

- **Always consider the possibility of a CHC-associated thromboembolism when presented with a woman who has symptoms.**

**Further information on the safety concern and the recommendations**

Many studies have evaluated the risk of VTE (deep vein thrombosis, pulmonary embolism) among users of different CHCs. Based on the totality of the data it is concluded that VTE risk differs between products - with the lower risk products being those containing the progestogens levonorgestrel, norethisterone and norgestimate. For some products there are currently insufficient data to know how the risk compares with the lower risk products.

Best estimates of the risk of VTE with a number of ethinylestradiol/progestogen combinations compared with the risk associated with levonorgestrel-containing pills are shown in table 1.

Compared with pregnancy and the postpartum period, the risk of VTE associated with using CHCs is lower.

**Table 1: Risk of VTE with combined hormonal contraceptives**

<b>Progestogen in CHC (combined with ethinylestradiol, unless stated)</b>	<b>Relative risk vs Levonorgestrel</b>	<b>Estimated incidence (per 10,000 women per year of use)</b>
Non-pregnant non-user	-	2
Levonorgestrel	Ref	5-7
Norgestimate / Norethisterone	1.0	5-7
Gestodene / Desogestrel / Drospirenone	1.5-2.0	9-12
Etonogestrel / Norelgestromin	1.0-2.0	6-12
Chlormadinone / Dienogest/ Nomegestrel acetate (E2)	TBC <sup>1</sup>	TBC <sup>1</sup>

E2 – estradiol; TBC – to be confirmed

<sup>1</sup> Further studies are ongoing or planned to collect sufficient data to estimate the risk for these products.

Prescribers should be aware of current product information and clinical guidance when discussing the most suitable type of contraceptive for any woman. The risk of VTE is highest during the first year of using any CHC, or upon re-starting CHCs after a break of 4 or more weeks. The risk of VTE is also higher in the presence of intrinsic risk factors. Risk factors for VTE change over time and an individual’s risk should be re-evaluated periodically. To facilitate earlier diagnosis all women with signs and symptoms should be asked if they are taking any medicines “*or if they are using a combined hormonal contraceptive*”. You are reminded that a significant proportion of thromboembolisms are not preceded by any obvious signs or symptoms.

It is known that the risk of ATE (myocardial infarction, cerebrovascular accident) is also increased with use of CHCs, however there are insufficient data available to demonstrate whether this risk varies between different products.

The decision about which product to use should be taken only after a discussion with the woman that includes the level of VTE risk associated with different products; how her current risk factors influence the risk of VTE and ATE, and exploration of her preferences.

*A prescribing checklist will be developed to help guide this discussion. Further information for women will be provided at the following website: [www.medicinesauthority.gov.mt/dhpc](http://www.medicinesauthority.gov.mt/dhpc)*

Product information will be updated to reflect our current understanding of the available evidence and to make information as clear as possible. We have also taken this opportunity to update baseline VTE rates to reflect current evidence. These increased rates are likely due to improvements in VTE diagnosis and reporting and an increase in obesity over time.

#### **Call for reporting**

Any suspected adverse reactions and medication errors can be reported via the national Adverse Drug Reactions (ADRs) reporting system. Report forms can be downloaded from [www.medicinesauthority.gov.mt/adrportal](http://www.medicinesauthority.gov.mt/adrportal) and posted to Medicines Authority Post-licensing Directorate, 203, Level 3, Rue D'Argens, Gżira GŻR 1368, MALTA, or sent by email to [postlicensing.medicinesauthority@gov.mt](mailto:postlicensing.medicinesauthority@gov.mt)

#### **Company contact point**

Contact point details for further information are given in the product information of the medicine (SmPC and Package Leaflet).

Post Licensing Directorate  
Medicines Authority

#### **Disclaimer**

This Direct Healthcare Professional Communication has been submitted to you on behalf of Actavis Group PTC ehf ; Bayer Pharma ; Janssen-Cilag International ; Metropolis Healthcare Ltd; Merck Sharp and Dohme Ltd ; Pfizer Hellas S.A. ; Stragen UK Ltd